Forty Seven has patented a method to treat CD20+ cancer, specifically Non-Hodgkin’s lymphoma refractory to rituximab. The method involves administering anti-CD47 and anti-CD20 antibodies in cycles, achieving an overall response rate of at least 40% in human subjects. GlobalData’s report on Forty Seven gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Forty Seven Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Forty Seven, was a key innovation area identified from patents.

Treatment of cd20+ cancer using anti-cd47 antibody

Source: United States Patent and Trademark Office (USPTO). Credit: Forty Seven Inc

A recently granted patent (Publication Number: US11891450B2) outlines a method for effectively treating or reducing cancer burden in human subjects with Non-Hodgkin's lymphoma (NHL) who are refractory to rituximab. The method involves administering a combination of anti-CD47 and anti-CD20 antibodies in specific dosages over two cycles, resulting in an overall response rate of at least 40%. The treatment protocol includes selecting refractory subjects, administering the antibodies over four weeks in each cycle, and potentially repeating the cycles until a clinical benefit is reduced or lost.

The patent also specifies that the method can be applied to various types of NHL, such as indolent lymphoma, follicular lymphoma (FL), or diffuse large B cell lymphoma (DLBCL), and to subjects who have relapsed or refractory to multiple prior lines of cancer therapy. The use of specific antibodies, including Hu5F9-G4 for anti-CD47 and rituximab for anti-CD20, is highlighted, along with the option to administer the antibodies concurrently or sequentially. Additionally, the patent details the dosages, administration routes, and potential adjustments based on the subjects' response to the treatment. Overall, the method described in the patent aims to provide an effective treatment option for refractory NHL patients, achieving a significant overall response rate while considering individual variations and clinical outcomes.

To know more about GlobalData’s detailed insights on Forty Seven, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies